Sai Life Sciences

Hyderabad, India Founded: 1999 • Age: 27 yrs Listed
Complex small molecules are discovered, developed, and manufactured for pharmaceuticals.

About Sai Life Sciences

Sai Life Sciences is a publicly listed company based in Hyderabad (India) founded in 1999. Complex small molecules are discovered, developed, and manufactured for pharmaceuticals. Sai Life Sciences has raised $112.18 million across 10 funding rounds from investors including Tata Capital, TPG and HBM Healthcare Investments. The company has 3,077 employees. Sai Life Sciences was last valued at $563.73 million in July 2024. Its chief executive, as recorded, is Krishna Kanumuri. Its website sailife.com draws about 39 thousand monthly visits. Its Indian entity Sai Life Sciences Limited reported revenue of β‚Ή2,242 Cr. Its focus areas include Biopharma Outsourcing, CRO, Drug Discovery and Medicinal Chemistry.

Company details

Sai Life Sciences was founded in 1999 in Hyderabad, India, and operates in the pharmaceutical sector. Services in drug discovery, development, and manufacturing of complex small molecules are offered, including synthetic and medicinal chemistry, pre-clinical toxicology, and DMPK studies. CMC operations cover pre-formulation, analytical development, stability studies, lyophilization, liposome processes, and formulation development.

Recognitions & Rankings of Sai Life Sciences

India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#352
Valuation
₹15,920 Cr
  • Headquarters Hyderabad, India
  • Employees 3,077
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Website sailife.com
  • Social LinkedIn X Facebook Instagram YouTube
  • Legal Name Sai Life Sciences Ltd.
Key Metrics
  • Market Cap
    ₹38,018 Cr

    SAILIFE · NSE

  • Share Price
    ₹1,801.00

    +0.70% today

  • Revenue
    ₹2,192 Cr

    FY 2025-26 · +29.4% YoY

  • EBITDA
    ₹625 Cr

    Margin 28.5%

  • Net Profit
    ₹356 Cr

    FY 2025-26 · +107.4% YoY

  • P/E (TTM)
    97.4x

    P/B 13.9x

  • ROE
    15.1%

    ROCE 19.1%

  • Debt / Equity
    0.14

    Interest cover 8.9x

  • Total Equity Funding
    $112.18M (USD)

    in 10 rounds

  • Latest Funding Round
    $1.14M (USD), Angel Round

    Jul 2024

  • Investors
  • Employee Count
    3,077

Apps and channels of Sai Life Sciences

its YouTube channel Sai Life Sciences has 1.48K subscribers and 30 videos.

Sai Life Sciences
YouTube 1.48K subscribers 30 videos Science & Technology
Open channel

Videos from Sai Life Sciences

The most watched videos on Sai Life Sciences's YouTube channel, Sai Life Sciences (1.48K subscribers). Click a video to play it here.

What makes #SaiLifeSciences a trusted partner in bringing new medicines to life?
6.9K views
Vaishnavi Dharmapuri I Executive, Process Engineering I Women In Pharma I Sai Life Sciences
3.6K views
Explore Sai Life Sciences through a Live 360 Virtual Tour!
3.2K views
Naga Swarna V I Research Chemist P R&D I Women In Pharma I Sai Life Sciences
2.3K views

More on Sai Life Sciences.

Funding Insights of Sai Life Sciences

Sai Life Sciences has successfully raised a total of $112.18M across 10 strategic funding rounds. The most recent funding activity was a Angel Round of $1.14 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $112.18M
  • Total Rounds 10
  • Last Round Angel Round β€” $1.14M
  • First Round $1.57M

    (Aug 2006)

  • Investors Count 15

All 10 funding rounds of Sai Life Sciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jul 2024$1.14MAngel Round$563.73MFred Cohen
–
Jul 2022$99,467Angel Round$394.5MJagdish V Dore
–
Jul 2021$106,922Angel Round$β€’β€’β€’β€’β€’Jagdish V Dore
–
Jul 2020$106,065Angel Round$β€’β€’β€’β€’β€’Jagdish V Dore
–
Mar 2019$41.65MSeries C$β€’β€’β€’β€’β€’TPG
Jun 2018$4MSeries C–HBM Healthcare Investments
–
Jan 2016$31MSeries C$‒‒‒‒‒–
Apr 2008$20.02MSeries B$β€’β€’β€’β€’β€’MPM Capital
–
Oct 2007$12.5MSeries B–Sequoia Capital
–
Aug 2006$1.57MSeries A$β€’β€’β€’β€’β€’Advantium
Valuation history
DateValuationStage
Jul 2024$563.73Mβ€’β€’β€’β€’β€’β€’β€’β€’
Jul 2022$394.5Mβ€’β€’β€’β€’β€’β€’β€’β€’
Jul 2021$β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’
Jul 2020$β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’
Mar 2019$β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’
Jan 2016$β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’
Apr 2008$β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’
Aug 2006$β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’
Premium access

Full valuation and stage history of Sai Life Sciences

Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.

  • All valuation points
  • Stage changes
  • Dates
  • Exports

Verified entity values are shown only after access is granted.

Last known valuation $563.73M (Jul 2024). 15 investors in total: 8 institutional and 7 angel.

Investors in Sai Life Sciences

Sai Life Sciences has secured backing from 15 investors, including angel, venture fund, and institutional investors. Prominent investors backing the company include Tata Capital, TPG and HBM Healthcare Investments.

All
Venture Fund
Institutional
Angel
InvestorDescriptionFounded YearDomainLocation
Fund of funds focused on pre-seed and seed-stage companies
1992tpg.comFort Worth, United States
Late-stage life sciences investments are managed via VC and PE.
hbmpartners.comZug, Switzerland
Life sciences focused VC firm funding companies in the US and Europe
2001hbmhealthcare.comZug, Switzerland
Sequoia Capital is engaged in venture capital investments.
1972sequoiacap.com
Diversified non-banking financial services are provided by Tata Capital.
2007tatacapital.comMumbai, India
Invests in biotech firms developing life-saving drugs and technologies.
mpmcapital.com

Fred Cohen

Indian angel investor, active in tech startups, limited public data available.
unknown_6de7c854dfcd4dd3b

Jagdish V Dore

unknown_d2b9e4a5429b478f9
Premium access

Investor details for Sai Life Sciences

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Sai Life Sciences Limited (Sai Life Sciences)

Sai Life Sciences Limited is the primary company behind Sai Life Sciences. The boards of the 3 registered companies of Sai Life Sciences currently have 6 directors; the longest-serving is Krishnamraju Kanumuri, appointed in 2019. 31 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Krishnamraju Kanumuri
DIN 00064614
Director03 Dec 20196 yrs 11 moSai Life Drugform Private Limited, Sai Life Pharma Private Limited, Sai Life Sciences Limited
Ranga Raju Kanumuri
DIN 00043186
Director03 Dec 20196 yrs 11 moSai Life Drugform Private Limited, Sai Life Pharma Private Limited, Sai Life Sciences Limited
Ramesh Ganesh Iyer
DIN 00220759
Director21 May 20242 yrs 6 moSai Life Sciences Limited
Suchita Sharma
DIN 10656028
Director10 Jun 20242 yrs 5 moSai Life Sciences Limited
Dinesh Vinoobhai Patel
DIN 11010657
Director24 Mar 20251 yr 7 moSai Life Sciences Limited
Sivaramakrishnan Chittor
DIN 01092158
Whole-time director28 Apr 20251 yr 6 moSai Life Sciences Limited

People of Sai Life Sciences

86 people are tracked at Sai Life Sciences (42 in leadership, 4 in board & advisors, 40 in team); the tracked headcount is 3,077.

NameRoleGroup
Prathima Kanumuri
Leadership
Krishna Kanumuri
CEO & MDLeadership
Venkata Ramana Sirivolu
Senior DirectorLeadership
Sonela Cavicke
Vice President, Head Of Discovery Business Development, North AmericaLeadership
Abhijit Das
Deputy General Manager - Operational ExcellenceLeadership
Monish Kulkarni
Associate Vice President Human ResourcesLeadership
Siva Chittor
Chief Financial OfficerLeadership
Nimmagadda Sri Krishna
Associate DirectorLeadership
Carol Chouest
Senior Director Of Business DevelopmentLeadership
Prabhu Gudelli
Senior Vice President ManufacturingLeadership
Kandi Vijeender
Associate DirectorLeadership
Sidhartha Das
SVP & Head, Human ResourcesLeadership
Yadu Kishore Devayajanam
Director - Human ResourcesLeadership
Hitesh Desai
Sr.director & Head-hr (manufacturing)Leadership
Anil Jagdhane
Deputy General ManagerLeadership
Tuneer Ghosh
SVP & Head, CMC Business DevelopmentLeadership
Damodharen Muniyandi
Chief Quality OfficerLeadership
Bharadwaj Ps
DirectorLeadership
Maneesh Pingle
SVP & Head, Discovery Business DevelopmentLeadership
Abhishek Sinha
Associate DirectorLeadership

66 more people are available in the full profile.

Premium access

Complete people profiles for Sai Life Sciences

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Sai Life Sciences

Sai Life Sciences is a publicly listed company on the NSE with ticker symbol SAILIFE in India, operating in the Commercial services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date18 Dec 2024
  • Listed onNSE: SAILIFE · BSE: 544306
  • Listed entitySAI Life Sciences Ltd.
  • Exchange sectorCommercial services
  • ISININE570L01029
  • Share price₹1,436.00 (-1.8% on the day) · 2026-10-14
  • Market capitalisation₹31,062 Cr
  • Price to earnings84.8
  • EPS (diluted, trailing year)₹16.93
  • Volume (last session)208,147

Financials of Sai Life Sciences

Exchange-reported figures of Sai Life Sciences Limited, the listed company behind Sai Life Sciences (NSE: SAILIFE).

Financial Highlights

FY 2025-26 Β· Consolidated
Revenue
₹2,192 Cr
+29.4% YoY
EBITDA
₹625 Cr
+53.2% YoY
Profit After Tax
₹356 Cr
+107.4% YoY
Net Worth
₹2,484 Cr
+16.7% YoY
Total Assets
₹2,804 Cr
+12.0% YoY
Total Debt
₹288 Cr
-18.1% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue2,1921,6951,4651,217870760726
Revenue growth+29.4%+15.7%+20.4%+40.0%+14.4%+4.7%-
EBITDA625408287169126167168
EBITDA margin+28.5%+24.1%+19.6%+13.9%+14.5%+22.0%+23.1%
Profit before tax46622810916.419.7081.91109
Net profit35617182.7810.21(5.08)61.0976.34
Net profit margin+16.2%+10.1%+5.7%+0.8%-0.6%+8.0%+10.5%
EPS (β‚Ή)16.488.1646.895.673.5535.0646.59
Balance sheet
Total assets2,8042,5041,9241,8411,8411,5481,145
Net worth2,4842,128975888879863794
Total debt288352928932751637304
Cash & bank11146415986.3413076.4198.25
Net working capital670960680681685595390
Cash flow
Cash from operations509314263219105(36.38)116
Cash from investing(395)(536)(191)(99.00)(102)(260)(262)
Cash from financing(124)301(95.30)(201)71.92296(4.07)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue659554602556537496580440
Revenue growth (YoY)+22.5%+11.7%+3.9%+26.5%+35.9%+77.5%--
Other income3.973.5415.818.3815.339.909.609.12
EBITDA186148177180146121158120
EBITDA margin+28.3%+26.7%+29.3%+32.3%+27.1%+24.4%+27.2%+27.2%
Depreciation48.1345.9445.3144.0839.7537.7237.4934.09
Interest10.947.647.839.709.3512.3610.8923.13
Profit before tax13197.9713913411280.7511971.65
Tax32.9624.6934.9933.8028.2020.3030.5317.80
Net profit98.3373.2810410083.8560.4588.2753.85
EPS (β‚Ή)4.583.424.874.713.932.904.142.84
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue2,1531,6421,4191,157841751725
Revenue growth+31.1%+15.7%+22.6%+37.6%+11.9%+3.6%-
EBITDA593392288167125164170
EBITDA margin+27.6%+23.9%+20.3%+14.4%+14.9%+21.9%+23.4%
Profit before tax45623212932.6822.3687.59114
Net profit34817595.2224.614.3865.3180.13
Net profit margin+16.2%+10.7%+6.7%+2.1%+0.5%+8.7%+11.1%
EPS (β‚Ή)16.128.3253.9213.768.9336.6548.92
Balance sheet
Total assets2,7632,4781,8991,8021,7901,5451,137
Net worth2,5082,1671,011913891868794
Total debt223287868869751637304
Cash & bank10845815280.0212470.1092.97
Net working capital641947697684690584401
Cash flow
Cash from operations49533025122188.38(25.94)109
Cash from investing(393)(565)(190)(111)(94.63)(279)(259)
Cash from financing(109)314(84.63)(190)80.95304(1.40)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue647547594549527483567429
Revenue growth (YoY)+22.9%+13.2%+4.8%+28.1%+37.9%+82.6%--
Other income3.843.5416.048.4514.9310.019.829.45
Total expenses469407426378387370413317
EBITDA178140168171140113154111
EBITDA margin+27.5%+25.6%+28.3%+31.1%+26.6%+23.4%+27.1%+25.9%
Depreciation44.4042.1341.1640.6036.2134.3334.1031.07
Interest9.335.986.168.067.7010.709.1621.66
Profit before tax12895.3313713011177.9812067.91
Tax32.3023.9934.3232.8427.9219.6230.5316.85

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 20 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue659554602556537496580440
Revenue growth (YoY)+22.5%+11.7%+3.9%+26.5%+35.9%+77.5%--
Other income3.973.5415.818.3815.339.909.609.12
EBITDA186148177180146121158120
EBITDA margin+28.3%+26.7%+29.3%+32.3%+27.1%+24.4%+27.2%+27.2%
Depreciation48.1345.9445.3144.0839.7537.7237.4934.09
Interest10.947.647.839.709.3512.3610.8923.13
Profit before tax13197.9713913411280.7511971.65
Tax32.9624.6934.9933.8028.2020.3030.5317.80
Net profit98.3373.2810410083.8560.4588.2753.85
EPS (β‚Ή)4.583.424.874.713.932.904.142.84
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue2,1921,6951,4651,217870760726
Revenue growth+29.4%+15.7%+20.4%+40.0%+14.4%+4.7%-
Other income49.1336.7829.0927.9728.1527.2917.84
Total expenses1,5681,2871,1781,048743593558
Employee cost683549495417301232214
EBITDA625408287169126167168
EBITDA margin+28.5%+24.1%+19.6%+13.9%+14.5%+22.0%+23.1%
Depreciation16713911999.4390.1679.5754.70
Interest40.8878.3487.5681.0254.4833.1421.70
Profit before tax46622810916.419.7081.91109
Tax11757.5726.436.423.4720.8232.76
Net profit35617182.7810.21(5.08)61.0976.34
Net profit margin+16.2%+10.1%+5.7%+0.8%-0.6%+8.0%+10.5%
EPS (β‚Ή)16.488.1646.895.673.5535.0646.59
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital21.1820.8418.0518.0117.9417.8216.38
Reserves & surplus2,4632,107957870861845777
Shareholders' funds (net worth)2,4842,128975888879863794
Minority interest0.000.000.000.000.000.000.00
Secured loans95.13129710699718603291
Unsecured loans19322421823333.8033.9812.42
Total debt288352928932751637304
Total liabilities2,8042,5041,9241,8411,8411,5481,145
Assets
Gross block2,6072,1161,6791,418937859810
Net block1,8151,4881,1801,037751701641
Capital work in progress27012410715141024690.96
Investments50.501.941.871.870.020.020.02
Inventories15111987.4414012776.3544.04
Sundry debtors374355256284243206270
Cash & bank balances11146415986.3413076.4198.25
Loans & advances728567443454444445201
Total current assets1,3641,505945964944804613
Total current liabilities693545265283259208222
Net working capital670960680681685595390
Total assets2,8042,5041,9241,8411,8411,5481,145
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash91.0511.9735.5311640.6241.40192
Net cash from operating activities509314263219105(36.38)116
Net cash from investing activities(395)(536)(191)(99.00)(102)(260)(262)
Net cash from financing activities(124)301(95.30)(201)71.92296(4.07)
Net change in cash(9.14)79.08(23.56)(80.25)75.15(0.78)(150)
Closing cash11146415986.3413076.4198.25
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+29.4%+15.7%+20.4%+40.0%+14.4%+4.7%-
EBITDA growth+53.2%+42.0%+70.0%+33.8%-24.6%-0.2%-
PBT growth+104.7%+108.5%+565.6%+69.2%-88.2%-24.9%-3.5%
Net income growth+107.4%+107.1%+710.8%+301.0%-108.3%-20.0%-
Revenue CAGR (3Y)+21.7%+24.9%+24.5%+18.8%+7.8%--
EBITDA CAGR (3Y)+54.7%+47.9%+19.7%+0.2%-10.4%--
Profitability & leverage
Net income margin+15.9%+10.0%+5.7%+0.8%+0.7%+8.0%+10.5%
Return on capital employed+19.1%+13.8%+10.5%+5.3%+3.1%+8.6%+12.1%
Return on net worth+15.1%+11.0%+8.9%+1.1%-0.6%+7.4%+10.1%
Debt / equity0.140.411.000.950.800.570.37
Long-term debt / equity0.070.200.490.430.310.200.10
Interest cover8.9329.1052.22116.64151.2137.7619.21
Efficiency & per share
Fixed asset turnover0.930.890.951.030.970.911.12
Inventory turnover16.2516.4312.919.148.5612.6216.40
Debtors turnover6.025.555.424.623.883.202.88
EPS (β‚Ή)16.488.1646.895.673.5535.0646.59
Dividend per share (β‚Ή)0.000.000.0038.3339.630.000.00
Book value per share (β‚Ή)117.28102.12551.96503.80500.21494.88484.03
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue647547594549527483567429
Revenue growth (YoY)+22.9%+13.2%+4.8%+28.1%+37.9%+82.6%--
Other income3.843.5416.048.4514.9310.019.829.45
Total expenses469407426378387370413317
EBITDA178140168171140113154111
EBITDA margin+27.5%+25.6%+28.3%+31.1%+26.6%+23.4%+27.1%+25.9%
Depreciation44.4042.1341.1640.6036.2134.3334.1031.07
Interest9.335.986.168.067.7010.709.1621.66
Profit before tax12895.3313713011177.9812067.91
Tax32.3023.9934.3232.8427.9219.6230.5316.85
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue2,1531,6421,4191,157841751725
Revenue growth+31.1%+15.7%+22.6%+37.6%+11.9%+3.6%-
Other income49.1337.3429.3327.9628.1527.2917.84
Total expenses1,5601,2501,131991716587556
Employee cost618486431354263204202
EBITDA593392288167125164170
EBITDA margin+27.6%+23.9%+20.3%+14.4%+14.9%+21.9%+23.4%
Depreciation15212610787.7779.7071.7752.36
Interest34.0871.9481.1574.3850.9832.1121.26
Profit before tax45623212932.6822.3687.59114
Tax11558.2633.788.456.6722.2833.95
Net profit34817595.2224.614.3865.3180.13
Net profit margin+16.2%+10.7%+6.7%+2.1%+0.5%+8.7%+11.1%
EPS (β‚Ή)16.128.3253.9213.768.9336.6548.92
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital21.1820.8418.0518.0117.9417.8216.38
Reserves & surplus2,4872,147993895873850777
Shareholders' funds (net worth)2,5082,1671,011913891868794
Secured loans95.13129710699718603291
Unsecured loans12815915717033.8033.9812.42
Total debt223287868869751637304
Total liabilities2,7632,4781,8991,8021,7901,5451,137
Assets
Gross block2,4131,9441,5261,270884815784
Net block1,7051,3781,074923701659617
Capital work in progress27012410715134523678.97
Investments16311480.2780.2763.5663.3622.38
Inventories15011886.0713812673.3342.93
Sundry debtors370353259277237203269
Cash & bank balances10845815280.0212470.1092.97
Loans & advances725565454457457446204
Total current assets1,3521,495951952944792609
Total current liabilities711548254268253208208
Net working capital641947697684690584401
Total assets2,7632,4781,8991,8021,7901,5451,137
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash85.125.1729.2110934.3136.12188
Net cash from operating activities49533025122188.38(25.94)109
Net cash from investing activities(393)(565)(190)(111)(94.63)(279)(259)
Net cash from financing activities(109)314(84.63)(190)80.95304(1.40)
Net change in cash(6.52)79.95(24.04)(79.80)74.70(1.81)(152)
Closing cash10845815280.0212470.1092.97
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+31.1%+15.7%+22.6%+37.6%+11.9%+3.6%-
EBITDA growth+51.3%+36.2%+72.6%+33.6%-23.9%-3.3%-
PBT growth+96.9%+79.6%+294.8%+46.2%-74.5%-23.2%+1.6%
Net income growth+99.2%+83.6%+286.9%+461.9%-93.3%-18.5%-
Revenue CAGR (3Y)+23.0%+25.0%+23.6%+16.9%+6.6%--
EBITDA CAGR (3Y)+52.6%+46.5%+20.6%-0.6%-10.6%--
Profitability & leverage
Net income margin+15.9%+10.6%+6.7%+2.1%+1.9%+8.7%+11.1%
Return on capital employed+18.7%+13.9%+11.4%+6.0%+3.7%+8.9%+12.6%
Return on net worth+14.6%+10.9%+9.9%+2.7%+0.5%+7.9%+10.6%
Debt / equity0.110.360.900.900.790.570.37
Long-term debt / equity0.040.160.410.390.310.180.09
Interest cover7.7327.0144.8894.03112.8134.7518.09
Efficiency & per share
Fixed asset turnover0.990.951.021.080.990.941.14
Inventory turnover16.0616.0712.668.778.4412.9316.61
Debtors turnover5.965.375.294.503.833.182.88
EPS (β‚Ή)16.128.3253.9213.768.9336.6548.92
Dividend per share (β‚Ή)0.000.000.0038.3339.630.000.00
Book value per share (β‚Ή)118.42104.00572.28517.79507.50486.92484.05

Timeline of Sai Life Sciences

5 dated milestones of Sai Life Sciences across 25 years, from founding to its latest funding, stage changes and deals.

  1. Founded Sai Life Sciences is founded.
  2. Funding First funding round of $1.6M.
  3. Milestone Reaches Minicorn status.
  4. Funding Latest funding round, Angel Round, of $1.1M.
  5. IPO Lists on the stock exchange (IPO).

Web traffic of Sai Life Sciences

The website of Sai Life Sciences (sailife.com) receives about 38.9K visits a month and ranks #915,798 among all websites worldwide, #1,098 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    38.9K

    ▲ 24.1% vs previous month

  • Unique visitors
    13.3K

    per month

  • Global rank
    #915,798

    among all websites

  • Category rank
    #1,098

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Sai Life Sciences. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
cuebiopharma.com
100%
4.9K#7,063,180View details
sherlock.bio
100%
2.8K#4,929,420View details
ornatx.com
97%
4.4K#3,250,511View details
dynotx.com
96%
14.4K#2,089,404View details
bioagilytix.com
94%
41.6K#919,146View details
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 12 similar websites and full traffic analytics for Sai Life Sciences

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 12 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as Sai Life Sciences (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Developer of integrated contract research development and manufacturing services
2007Bengaluru, Karnataka, IndiaUSD 35.74 MUSD 226.38 M2,062
Pharmaceutical and biotechnology company
2005Hyderabad, Telangana, IndiaUSD 229.73 MUSD 726.15 M548
India's leading healthcare products distribution platform
2018Mumbai, Maharashtra, IndiaUSD 59.67 MUSD 702.49 M557
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Sai Life Sciences

Premium access

Complete news archive for Sai Life Sciences

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Sai Life Sciences

Sai Life Sciences was founded in 1999 and raised its 1st funding round 7 years after it was founded.

Sai Life Sciences is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.

Krishna Kanumuri is the CEO of Sai Life Sciences, as recorded in our data.

Sai Life Sciences is a funded company, having raised a total of $112.18M across 10 funding rounds to date. The company's 1st funding round was a Series A of $1.57M, raised on Aug 2006.

Sai Life Sciences has 3,077 employees.

The primary company behind Sai Life Sciences, Sai Life Sciences Limited, reported revenue of β‚Ή2,242 Cr for FY 2026, up 29% year on year.

Sai Life Sciences was founded in 1999 in Hyderabad, India, and operates in the pharmaceutical sector. Services in drug discovery, development, and manufacturing of complex small molecules are offered, including synthetic and medicinal chemistry, pre-clinical toxicology, and DMPK studies. CMC operations cover pre-formulation, analytical development, stability studies, lyophilization, liposome processes, and formulation development.

Yes, Sai Life Sciences is publicly traded on NSE under the ticker symbol SAILIFE.

Sai Life Sciences has 15 investors. Key investors include Tata Capital, TPG, HBM Healthcare Investments, Fred Cohen, and Jagdish V Dore.

The valuation of Sai Life Sciences is $563.73M as of Jul 2024.

Sai Life Sciences is associated with 3 legal entities: Sai Life Sciences Limited, Sai Life Drugform Private Limited, Sai Life Pharma Private Limited.

The legal entities of Sai Life Sciences currently have 9 directors, including Krishnamraju Kanumuri, Ranga Raju Kanumuri, Runa Karan and others.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available